Dicerna Pharmaceuticals (DRNA) Stock Price, News & Analysis

Company Overview

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Key Stats

• Today's Range: $38.22 to $38.22
• 50-Day Range: $37.81 to $38.25
• 52-Week Range: $19.06 to $40.14
• Volume: N/A
• Average Volume: 1.34 million shs
• Market Capitalization: $2.99 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Dicerna Pharmaceuticals Stock Analysis - MarketRank™

Dicerna Pharmaceuticals scored higher than 22% of companies evaluated by MarketBeat, and ranked 886th out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Dicerna Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Dicerna Pharmaceuticals are expected to grow in the coming year, from ($1.59) to ($1.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dicerna Pharmaceuticals is -23.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dicerna Pharmaceuticals is -23.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dicerna Pharmaceuticals has a P/B Ratio of 20.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for DRNA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dicerna Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Dicerna Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.77

Short Interest

There is no current short interest data available for DRNA.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Dicerna Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dicerna Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.20% of the stock of Dicerna Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.91% of the stock of Dicerna Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DRNA Stock Analysis - Frequently Asked Questions

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) released its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.19. The biopharmaceutical company had revenue of $62.95 million for the quarter, compared to analyst estimates of $58.83 million. Dicerna Pharmaceuticals had a negative net margin of 64.53% and a negative trailing twelve-month return on equity of 103.08%.

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Marvell Technology (MRVL), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and PayPal (PYPL).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 11/16/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:DRNA
• CUSIP: N/A
• CIK: 1399529
• Web: www.dicerna.com
• Phone: (617) 621-8097
• Fax: 617-612-6298
• Employees: 302
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-112,750,000.00
• Net Margins: -64.53%
• Pretax Margin: -63.82%
• Return on Equity: -103.08%
• Return on Assets: -16.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.46
• Quick Ratio: 2.46

Sales & Book Value

• Annual Sales: $164.31 million
• Price / Sales: 18.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.84 per share
• Price / Book: 20.77

Miscellaneous

• Outstanding Shares: 78,129,000
• Free Float: 70,160,000
• Market Cap: $2.99 billion
• Optionable: Optionable
• Beta: 0.80